{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:33:10Z","timestamp":1794047590988,"version":"4.8.0"},"reference-count":293,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.594556","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T05:53:25Z","timestamp":1605678805000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":69,"title":["Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia"],"prefix":"10.3389","volume":"11","author":[{"given":"Valentina","family":"Griggio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Perutelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Boccellato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candida","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Coscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","article-title":"Chronic lymphocytic leukaemia: from genetics to treatment","volume":"16","author":"Bosch","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a026740","article-title":"Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia","volume":"7","author":"Purroy","year":"2017","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.142679","article-title":"Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk","volume":"102","author":"van Attekum","year":"2017","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07635.x","article-title":"Oligoclonal TRBV gene usage among CD8(+) T cells in monoclonal B lymphocytosis and CLL","volume":"145","author":"Lanasa","year":"2009","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.183954","article-title":"Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome","volume":"103","author":"Criado","year":"2018","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-010-8188-4","article-title":"Immunologic aspects of monoclonal B-cell lymphocytosis","volume":"49","author":"Lanasa","year":"2011","journal-title":"Immunol Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2019.06.002","article-title":"Monoclonal B-cell lymphocytosis","volume":"32","author":"Maitre","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.187","article-title":"Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls","volume":"27","author":"Moreira","year":"2013","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.235","article-title":"Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis","volume":"30","author":"Solomon","year":"2016","journal-title":"Leukemia"},{"key":"B12","first-page":"35","article-title":"Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia","volume":"9","author":"Dasanu","year":"2007","journal-title":"Med Gen Med Medscape Gen Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.12.004","article-title":"Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches","volume":"23","author":"Morrison","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw072","article-title":"Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia","volume":"27","author":"Falchi","year":"2016","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.03.004","article-title":"Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections","volume":"32","author":"Hilal","year":"2018","journal-title":"Blood Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.011","article-title":"Autoimmune complications of chronic lymphocytic leukemia","volume":"33","author":"Hamblin","year":"2006","journal-title":"Semin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12020282","article-title":"Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs","volume":"12","author":"Vitale","year":"2020","journal-title":"Cancers"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and Venetoclax for First-Line Treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00491","article-title":"Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Na\u00efve and Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Rogers","year":"2020","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.151","article-title":"Immunotherapeutic strategies including transplantation: eradication of disease","volume":"2013","author":"Gribben","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21051825","article-title":"Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions","volume":"21","author":"Arruga","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02720","article-title":"Molecular Interactions Between Innate and Adaptive Immune Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications","volume":"9","author":"Haseeb","year":"2018","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15918","article-title":"Chronic lymphocytic leukaemia: the role of T cells in a B cell disease","volume":"186","author":"Man","year":"2019","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0873-2","article-title":"T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease","volume":"34","author":"Roessner","year":"2020","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2568-2","article-title":"Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia","volume":"144","author":"Wang","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000497208","article-title":"Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia","volume":"42","author":"Hadadi","year":"2019","journal-title":"Oncol Res Treat"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.503820","article-title":"Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia","volume":"51","author":"Gonzalez-Rodriguez","year":"2010","journal-title":"Leukemia Lymphoma"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07070.x","article-title":"Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia","volume":"141","author":"Palmer","year":"2008","journal-title":"Br J Haematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1330235","DOI":"10.1080\/2162402X.2017.1330235","article-title":"NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors","volume":"6","author":"MacFarlane","year":"2017","journal-title":"Oncoimmunology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e108326","DOI":"10.1371\/journal.pone.0108326","article-title":"Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia","volume":"9","author":"Huergo-Zapico","year":"2014","journal-title":"Correlation Progress Dis PLoS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03521.x","article-title":"Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia","volume":"135","author":"Costello","year":"2012","journal-title":"Immunology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.240","article-title":"Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion","volume":"28","author":"Le Garff-Tavernier","year":"2014","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1046\/j.1365-2141.2001.02906.x","article-title":"Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias","volume":"114","author":"Lowdell","year":"2001","journal-title":"Br J Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910270310","article-title":"Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia","volume":"27","author":"Ziegler","year":"1981","journal-title":"Int J Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000203709","article-title":"Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha","volume":"96","author":"Katrinakis","year":"1996","journal-title":"Acta Haematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/leu.2008.15","article-title":"NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G","volume":"22","author":"Maki","year":"2008","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3109\/10428199209049804","article-title":"Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells","volume":"7","author":"Jewell","year":"1992","journal-title":"Leukemia Lymphoma"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830280305","article-title":"Unmasking of cryptic natural killer (NK) cell recognition sites on chronic lymphocytic leukemia lymphocytes","volume":"28","author":"Spitz","year":"1988","journal-title":"Am J Hematol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9624-5","article-title":"Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy","volume":"32","author":"Veuillen","year":"2012","journal-title":"J\u00a0Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e1226720","DOI":"10.1080\/2162402X.2016.1226720","article-title":"Therapeutic CD94\/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia","volume":"5","author":"McWilliams","year":"2016","journal-title":"Oncoimmunology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e1353856","DOI":"10.1080\/2162402X.2017.1353856","article-title":"Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia","volume":"6","author":"Villa-Alvarez","year":"2017","journal-title":"Oncoimmunology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30427","article-title":"HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia","volume":"123","author":"Wagner","year":"2017","journal-title":"Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.095281","article-title":"HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism","volume":"99","author":"Rizzo","year":"2014","journal-title":"Haematologica"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1097\/HS9.0000000000000308","article-title":"Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling","volume":"3","author":"Hofland","year":"2019","journal-title":"HemaSphere"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12097","article-title":"NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma","volume":"7","author":"Parry","year":"2016","journal-title":"Oncotarget"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.74","article-title":"The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia","volume":"24","author":"Nuckel","year":"2010","journal-title":"Leukemia"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00454","article-title":"Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells","volume":"7","author":"Sanchez-Martinez","year":"2016","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-476606","article-title":"Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity","volume":"121","author":"Reiners","year":"2013","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300187","article-title":"Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy","volume":"191","author":"Laprevotte","year":"2013","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"106350","DOI":"10.1016\/j.intimp.2020.106350","article-title":"IL-27 impact on NK cells activity: Implication for a robust anti-tumor response in chronic lymphocytic leukemia","volume":"82","author":"Hemati","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.02.006","article-title":"Interleukin-21 and rituximab enhance NK cell functionality in patients with B-cell chronic lymphocytic leukaemia","volume":"35","author":"Eskelund","year":"2011","journal-title":"Leukemia Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2005.12.008","article-title":"Analysis of the effect of different NKT cell subpopulations on the activation of CD4 and CD8 T cells, NK cells, and B cells","volume":"34","author":"Lin","year":"2006","journal-title":"Exp Hematol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/ni.3047","article-title":"Regulatory iNKT cells lack expression of the transcription factor PLZF and control the homeostasis of T(reg) cells and macrophages in adipose tissue","volume":"16","author":"Lynch","year":"2015","journal-title":"Nat Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.02.003","article-title":"Chronic Lymphocytic Leukemia: A Review of Front-line Treatment Options, With a Focus on Elderly CLL Patients","volume":"18","author":"O\u2019Reilly","year":"2018","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/ni851","article-title":"CD1-dependent dendritic cell instruction","volume":"3","author":"Vincent","year":"2002","journal-title":"Nat Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.072835","article-title":"Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy","volume":"98","author":"Weinkove","year":"2013","journal-title":"Haematologica"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.08.002","article-title":"Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8(+) invariant natural killer T cells","volume":"183","author":"Ghnewa","year":"2017","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-751065","article-title":"Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis","volume":"129","author":"Gorini","year":"2017","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.12.015","article-title":"CD1d expression is higher in chronic lymphocytic leukemia patients with unfavorable prognosis","volume":"38","author":"Bojarska-Junak","year":"2014","journal-title":"Leukemia Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10372","article-title":"CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells","volume":"7","author":"Zaborsky","year":"2016","journal-title":"Oncotarget"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.7484","article-title":"Intracellular IL-4 and IFN-gamma expression in iNKT cells from patients with chronic lymphocytic leukemia","volume":"15","author":"Bojarska-Junak","year":"2018","journal-title":"Oncol Lett"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11723","article-title":"CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes","volume":"109","author":"Fais","year":"2004","journal-title":"Int J Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2417","article-title":"Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid","volume":"64","author":"Poggi","year":"2004","journal-title":"Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1182\/blood-2011-02-339135","article-title":"Differentiation of human peripheral blood Vdelta1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells","volume":"118","author":"Correia","year":"2011","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0597","article-title":"Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion\/Differentiation and Preclinical Proof of Concept","volume":"22","author":"Almeida","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-011-0704-8","article-title":"V\u03b39V\u03b42 T cell-based immunotherapy in hematological malignancies: from bench to bedside","volume":"68","author":"Castella","year":"2011","journal-title":"Cell Mol Life Sci CMLS"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-417519","article-title":"Dysfunctional Vgamma9Vdelta2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells","volume":"120","author":"Coscia","year":"2012","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-822569","article-title":"Improving CLL Vgamma9Vdelta2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib","volume":"132","author":"de Weerdt","year":"2018","journal-title":"Blood"},{"key":"B71","article-title":"The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response","volume":"63","author":"Orsini","year":"2003","journal-title":"Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10093","article-title":"Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia","volume":"7","author":"Toniolo","year":"2016","journal-title":"Oncotarget"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12172","article-title":"High functional CD70 expression on \u03b1-type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia","volume":"79","author":"Junevik","year":"2014","journal-title":"Scand J Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1149-5","article-title":"Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria","volume":"61","author":"Palma","year":"2012","journal-title":"Cancer Immunol Immunother CII"},{"key":"B75","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/ejh.13065","article-title":"Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients","volume":"101","author":"Palma","year":"2018","journal-title":"Eur J Haematol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2011.02580.x","article-title":"Tumour-loaded \u03b1-type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia produce a superior NK-, NKT- and CD8+ T cell-attracting chemokine profile","volume":"74","author":"Gustafsson","year":"2011","journal-title":"Scand J Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2009.02249.x","article-title":"Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production","volume":"69","author":"Adamson","year":"2009","journal-title":"Scand J Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1981.tb07274.x","article-title":"Unusual T-cell phenotype in advanced B-chronic lymphocytic leukaemia","volume":"49","author":"Matutes","year":"1981","journal-title":"Br J Haematol"},{"key":"B79","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.129.5.2305","article-title":"Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies","volume":"129","author":"Platsoucas","year":"1982","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B80","article-title":"Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type","volume":"49","author":"Herrmann","year":"1982","journal-title":"Clin Exp Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)90944-1","article-title":"Clinical significance of T-cells in chronic lymphocytic leukaemia","volume":"2","author":"Catovsky","year":"1974","journal-title":"Lancet (London England)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2630","article-title":"Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression","volume":"18","author":"Nunes","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9941","article-title":"Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3639","article-title":"Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features","volume":"102","author":"Guarini","year":"2003","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151100","article-title":"T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma","year":"2017","journal-title":"Haematologica"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00194-1","article-title":"T type 1\/type 2 subsets balance in B-cell chronic lymphocytic leukemia\u2013the three-color flow cytometry analysis","volume":"26","author":"Podhorecka","year":"2002","journal-title":"Leukemia Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16316","article-title":"TBET-expressing Th1 CD4(+) T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in E\u00b5-TCL1 mice","volume":"189","author":"Roessner","year":"2020","journal-title":"Br J Haematol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001091","article-title":"Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses","volume":"4","author":"Manna","year":"2020","journal-title":"Blood Adv"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0250-6","article-title":"Control of chronic lymphocytic leukemia development by clonally-expanded CD8(+) T-cells that undergo functional exhaustion in secondary lymphoid tissues","volume":"33","author":"Hanna","year":"2019","journal-title":"Leukemia"},{"key":"B91","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.158.3.1482","article-title":"Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia","volume":"158","author":"Serrano","year":"1997","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(97)00152-5","article-title":"Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment","volume":"22","author":"Van den Hove","year":"1998","journal-title":"Leukemia Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.673224","article-title":"Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia","volume":"53","author":"Tonino","year":"2012","journal-title":"Leukemia Lymphoma"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-518183","article-title":"CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia","volume":"123","author":"te Raa","year":"2014","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3017","article-title":"Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia","volume":"22","author":"Vardi","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e1432328","DOI":"10.1080\/2162402X.2018.1432328","article-title":"Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL","volume":"7","author":"Blanco","year":"2018","journal-title":"Oncoimmunology"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"Gorgun","year":"2005","journal-title":"J Clin Invest"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35017","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"B101","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.celrep.2016.02.084","article-title":"Human Cytotoxic T Lymphocytes Form Dysfunctional Immune Synapses with B Cells Characterized by Non-Polarized Lytic Granule Release","volume":"15","author":"Kabanova","year":"2016","journal-title":"Cell Rep"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-448332","article-title":"Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide","volume":"121","author":"Ramsay","year":"2013","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8(+) T cells and impede CAR T-cell efficacy","volume":"134","author":"van Bruggen","year":"2019","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403907","article-title":"Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia","volume":"19","author":"Motta","year":"2005","journal-title":"Leukemia"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1159\/000381468","article-title":"Numbers of CD8+PD-1+ and CD4+PD-1+ Cells in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Are Independent of Binet Stage and Are Significantly Higher Compared to Healthy Volunteers","volume":"134","author":"Novak","year":"2015","journal-title":"Acta Haematol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.2967","article-title":"Prognostic significance of PD-1 expression on peripheral blood CD4+ T cells in patients with newly diagnosed chronic lymphocytic leukemia","volume":"125","author":"Rusak","year":"2015","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148965","article-title":"Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia","volume":"102","author":"Shapiro","year":"2017","journal-title":"Haematologica"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12880","article-title":"Frequency and functional characterization of exhausted CD8(+) T cells in chronic lymphocytic leukemia","volume":"98","author":"Taghiloo","year":"2017","journal-title":"Eur J Haematol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"e1371399","DOI":"10.1080\/2162402X.2017.1371399","article-title":"TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia","volume":"7","author":"Catakovic","year":"2017","journal-title":"Oncoimmunology"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e1465167","DOI":"10.1080\/2162402X.2018.1465167","article-title":"High-dimensional mass cytometry analysis revealed microenvironment complexity in chronic lymphocytic leukemia","volume":"7","author":"Wierz","year":"2018","journal-title":"Oncoimmunology"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.22034\/APJCP.2017.18.8.2269","article-title":"Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia","volume":"18","author":"Taghiloo","year":"2017","journal-title":"Asian Pacific J Cancer Prev APJCP"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-4217-1","article-title":"Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody","volume":"37","author":"Ciszak","year":"2016","journal-title":"Tumour Biol J Int Soc Oncodevelopment Biol Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16260","article-title":"Increased frequency of CD4(+) PD-1(+) HLA-DR(+) T cells is associated with disease progression in CLL","volume":"188","author":"Elston","year":"2020","journal-title":"Br J Haematol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Adv"},{"key":"B115","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/bloodadvances.2016000984","article-title":"Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment","volume":"1","author":"Serra","year":"2016","journal-title":"Blood Adv"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.08.010","article-title":"Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease","volume":"35","author":"D\u2019Arena","year":"2011","journal-title":"Leukemia Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2012.756110","article-title":"Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression","volume":"31","author":"Jadidi-Niaragh","year":"2013","journal-title":"Cancer Invest"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.966245","article-title":"A study for proposal of use of regulatory T cells as a prognostic marker and establishing an optimal threshold level for their expression in chronic lymphocytic leukemia","volume":"56","author":"Dasgupta","year":"2015","journal-title":"Leukemia Lymphoma"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1832968","DOI":"10.1155\/2017\/1832968","article-title":"Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies","volume":"2017","author":"D\u2019Arena","year":"2017","journal-title":"J Immunol Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.leukres.2017.07.004","article-title":"Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia","volume":"60","author":"Mpakou","year":"2017","journal-title":"Leukemia Res"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0318-3","article-title":"PI3Kdelta inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia","volume":"33","author":"Hanna","year":"2019","journal-title":"Leukemia"},{"key":"B122","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1080\/10428190902803677","article-title":"Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia","volume":"50","author":"Jak","year":"2009","journal-title":"Leukemia Lymphoma"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0642","article-title":"Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine","volume":"106","author":"Beyer","year":"2005","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701703","article-title":"The PI3K p110delta Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function","volume":"202","author":"Chellappa","year":"2019","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B125","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1365-2567.2011.03439.x","article-title":"Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro","volume":"133","author":"Lindqvist","year":"2011","journal-title":"Immunology"},{"key":"B126","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12967-018-1545-0","article-title":"Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients","volume":"16","author":"De Matteis","year":"2018","journal-title":"J Trans Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-3-030-38315-2_4","article-title":"IL-17 Signaling in the Tumor Microenvironment","volume":"1240","author":"Gorczynski","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.986479","article-title":"Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias","volume":"56","author":"Lad","year":"2015","journal-title":"Leukemia Lymphoma"},{"key":"B129","doi-asserted-by":"publisher","first-page":"e78091","DOI":"10.1371\/journal.pone.0078091","article-title":"Th17\/IL-17A might play a protective role in chronic lymphocytic leukemia immunity","volume":"8","author":"Hus","year":"2013","journal-title":"PLoS One"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-012-0628-4","article-title":"Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia","volume":"34","author":"Jadidi-Niaragh","year":"2013","journal-title":"Tumour Biol J Int Soc Oncodevelopment Biol Med"},{"key":"B131","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3324\/haematol.2011.047316","article-title":"Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance","volume":"97","author":"Jain","year":"2012","journal-title":"Haematologica"},{"key":"B132","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.intimp.2016.07.008","article-title":"Increased IL-10\/IL-17 ratio is aggravated along with the prognosis of patients with chronic lymphocytic leukemia","volume":"40","author":"Pang","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-015-8722-5","article-title":"Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes","volume":"63","author":"Sherry","year":"2015","journal-title":"Immunol Res"},{"key":"B134","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.leukres.2018.01.006","article-title":"Targeting the IL-17\/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo\/in vitro","volume":"66","author":"Zhu","year":"2018","journal-title":"Leukemia Res"},{"key":"B135","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-Derived Suppressor Cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.molimm.2017.11.014","article-title":"Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia","volume":"110","author":"Hanna","year":"2019","journal-title":"Mol Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08902.x","article-title":"Association of an increased frequency of CD14+HLA-DRlo\/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL)","volume":"156","author":"Gustafson","year":"2012","journal-title":"Br J Haematol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-546416","article-title":"CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.2808","article-title":"CD14(+)HLA-DR(low\/-) expression: A novel prognostic factor in chronic lymphocytic leukemia","volume":"9","author":"Liu","year":"2015","journal-title":"Oncol Lett"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1728747","article-title":"Monocytic myeloid-derived suppressor cells in chronic lymphocytic leukemia patients: a single center experience","volume":"61","author":"Zahran","year":"2020","journal-title":"Leukemia Lymphoma"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.305","article-title":"Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo","volume":"30","author":"Hanna","year":"2016","journal-title":"Leukemia"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.aah5509","article-title":"Tumor-derived exosomes modulate PD-L1 expression in monocytes","volume":"2","author":"Haderk","year":"2017","journal-title":"Sci Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.378","article-title":"CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D","volume":"31","author":"Bruns","year":"2017","journal-title":"Leukemia"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1320-7","article-title":"CXCL12 is a costimulator for CD4+ T cell activation and proliferation in chronic lymphocytic leukemia patients","volume":"62","author":"Borge","year":"2013","journal-title":"Cancer Immunol Immunother CII"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.126763","article-title":"Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy","volume":"100","author":"Visentin","year":"2015","journal-title":"Haematologica"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0344-1","article-title":"IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia","volume":"33","author":"Reda","year":"2019","journal-title":"Leukemia"},{"key":"B147","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.leukres.2017.02.011","article-title":"Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia","volume":"57","author":"Mauro","year":"2017","journal-title":"Leukemia Res"},{"key":"B148","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bjh.15146","article-title":"Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia","volume":"181","author":"Crassini","year":"2018","journal-title":"Br J Haematol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.3168.h8003168_3168_3174","article-title":"Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction","volume":"96","author":"Sampalo","year":"2000","journal-title":"Blood"},{"key":"B150","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1479-5876-8-111","article-title":"Quantification of newly produced B and T lymphocytes in untreated chronic lymphocytic leukemia patients","volume":"8","author":"Motta","year":"2010","journal-title":"J Trans Med"},{"key":"B151","doi-asserted-by":"crossref","DOI":"10.1136\/jcp.39.7.713","article-title":"Autoimmunity in chronic lymphocytic leukaemia","volume":"39","author":"Hamblin","year":"1986","journal-title":"J Clin Pathol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.10.2475.bloodjournal81102475","article-title":"Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases","volume":"81","author":"Kipps","year":"1993","journal-title":"Blood"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13712","article-title":"Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia","volume":"8","author":"Griggio","year":"2017","journal-title":"Oncotarget"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.146","article-title":"Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL","volume":"29","author":"Middleton","year":"2015","journal-title":"Leukemia"},{"key":"B155","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1002\/cncr.25983","article-title":"Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia","volume":"117","author":"Lee","year":"2011","journal-title":"Cancer"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000416","article-title":"Targeted Therapy in Chronic Lymphocytic Leukemia","volume":"25","author":"Kipps","year":"2019","journal-title":"Cancer J (Sudbury Mass)"},{"key":"B157","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30069","article-title":"Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity","volume":"122","author":"Thompson","year":"2016","journal-title":"Cancer"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leukemia Lymphoma"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32201","article-title":"Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients","volume":"145","author":"Stock","year":"2019","journal-title":"Int J Cancer"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib\u2013Findings from an Investigator-Initiated Phase II Study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B162","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.clml.2018.08.007","article-title":"Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","volume":"18","author":"Barrientos","year":"2018","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16148","article-title":"Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number","volume":"8","author":"Podhorecka","year":"2017","journal-title":"Oncotarget"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02832","article-title":"Long-Term Ibrutinib Therapy Reverses CD8(+) T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia","volume":"10","author":"Parry","year":"2019","journal-title":"Front Immunol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15516","article-title":"Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes","volume":"183","author":"Palma","year":"2018","journal-title":"Br J Haematol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.304","article-title":"Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1\/PD-L1 pathway","volume":"32","author":"Kondo","year":"2018","journal-title":"Leukemia"},{"key":"B169","doi-asserted-by":"publisher","first-page":"106432","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leukemia Res"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238154","article-title":"Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice","author":"Hanna","year":"2020","journal-title":"Haematologica"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115418","article-title":"Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate","volume":"132","author":"Gill","year":"2018","journal-title":"Blood"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"B174","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/hon.2667","article-title":"The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"37","author":"Zou","year":"2019","journal-title":"Hematol Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2794","article-title":"Combining T-cell-based immunotherapy with venetoclax elicits synergistic cytotoxicity to B-cell lines in vitro","author":"Murakami","year":"2020","journal-title":"Hematol Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax increases intra-tumoral effector T cells and anti-tumor efficacy in combination with immune checkpoint blockade","author":"Kohlhapp","year":"2020","journal-title":"Cancer Discovery"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8133","article-title":"Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia","volume":"29","author":"Chen","year":"2010","journal-title":"J Clin Oncol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1128540","article-title":"Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*","volume":"57","author":"Wendtner","year":"2016","journal-title":"Leukemia Lymphoma"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.47","article-title":"Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)","volume":"31","author":"Chanan-Khan","year":"2017","journal-title":"Leukemia"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.8623","article-title":"Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia","volume":"31","author":"Badoux","year":"2013","journal-title":"J Clin Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5890","article-title":"Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium","volume":"32","author":"James","year":"2014","journal-title":"J Clin Oncol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019031336","article-title":"Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL","volume":"3","author":"Strati","year":"2019","journal-title":"Blood Adv"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.935369","article-title":"Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"56","author":"Costa","year":"2015","journal-title":"Leukemia Lymphoma"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2476","article-title":"Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics","volume":"22","author":"Vitale","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.199","article-title":"A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL\/SLL","volume":"24","author":"Brown","year":"2010","journal-title":"Leukemia"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12714","article-title":"Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia","volume":"97","author":"Maurer","year":"2016","journal-title":"Eur J Haematol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1258698","article-title":"Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed\/refractory chronic lymphocytic leukemia. A multicenter phase I\u2013II GIMEMA trial","volume":"58","author":"Mauro","year":"2017","journal-title":"Leukemia Lymphoma"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017015263","article-title":"A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL","volume":"2","author":"Ujjani","year":"2018","journal-title":"Blood Adv"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.193854","article-title":"Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia","volume":"104","author":"Kater","year":"2019","journal-title":"Haematologica"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1608533","article-title":"Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia","volume":"60","author":"Soumerai","year":"2019","journal-title":"Leukemia Lymphoma"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1508669","article-title":"A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL)","volume":"60","author":"Chen","year":"2019","journal-title":"Leukemia Lymphoma"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1313230","article-title":"Lenalidomide in the treatment of chronic lymphocytic leukemia","volume":"26","author":"Itchaki","year":"2017","journal-title":"Expert Opin Invest Drugs"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578286","article-title":"How does lenalidomide target the chronic lymphocytic leukemia microenvironment","volume":"124","author":"Kater","year":"2014","journal-title":"Blood"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.4682.4682","article-title":"CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide","volume":"124","author":"Blocksidge","year":"2014","journal-title":"Blood"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111605","article-title":"Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1\/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling","volume":"132","author":"Ioannou","year":"2018","journal-title":"Blood"},{"key":"B199","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/14712598.2020.1734557","article-title":"The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia","volume":"20","author":"Hus","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1639","article-title":"Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance","volume":"101","author":"Manshouri","year":"2003","journal-title":"Blood"},{"key":"B201","doi-asserted-by":"publisher","first-page":"e1211220","DOI":"10.1080\/2162402X.2016.1211220","article-title":"Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia","volume":"5","author":"Vyas","year":"2016","journal-title":"Oncoimmunology"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2018.08.008","article-title":"An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies","volume":"154","author":"Qi","year":"2019","journal-title":"Methods (San Diego Calif)"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet (London England)"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"key":"B206","doi-asserted-by":"publisher","first-page":"LBA","DOI":"10.1182\/blood-2018-120779","article-title":"A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)","volume":"132","author":"Shanafelt","year":"2018","journal-title":"Blood"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2017.1333974","article-title":"Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis","volume":"22","author":"Wu","year":"2017","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1508624","article-title":"Anti-CD20 monoclonal antibodies: reviewing a revolution","volume":"14","author":"Casan","year":"2018","journal-title":"Hum Vaccines Immunother"},{"key":"B210","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/DDDT.S104869","article-title":"Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy","volume":"11","author":"Al-Sawaf","year":"2017","journal-title":"Drug Design Dev Ther"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet (London England)"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.334","article-title":"Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial","volume":"28","author":"Cortelezzi","year":"2014","journal-title":"Leukemia"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol"},{"key":"B214","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet (London England)"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14534","article-title":"A phase 1\/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"Br J Haematol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002118","article-title":"Ublituximab and umbralisib in relapsed\/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"134","author":"Lunning","year":"2019","journal-title":"Blood"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30216-3","article-title":"Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial","volume":"6","author":"Nastoupil","year":"2019","journal-title":"Lancet Haematol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leukemia Lymphoma"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02635-9","article-title":"A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma","volume":"109","author":"Ohmachi","year":"2019","journal-title":"Int J Hematol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128388","article-title":"Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R\/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)","volume":"134","author":"Staber","year":"2019","journal-title":"Blood"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.890182","article-title":"Anti-CD37 antibodies for chronic lymphocytic leukemia","volume":"14","author":"Robak","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"B224","article-title":"TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies","volume":"10","author":"Robak","year":"2009","journal-title":"Curr Opin Invest Drugs (London Engl 2000)"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-512137","article-title":"A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia","volume":"123","author":"Byrd","year":"2014","journal-title":"Blood"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14464","article-title":"Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia","volume":"176","author":"Robak","year":"2017","journal-title":"Br J Haematol"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0475-z","article-title":"Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed\/refractory chronic lymphocytic leukemia","volume":"33","author":"Stilgenbauer","year":"2019","journal-title":"Leukemia"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"key":"B229","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00175","article-title":"Antigen Loss Variants: Catching Hold of Escaping Foes","volume":"8","author":"Vyas","year":"2017","journal-title":"Front Immunol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B233","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.082248","article-title":"Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells","volume":"98","author":"Wong","year":"2013","journal-title":"Haematologica"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed\/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000218","article-title":"CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells","volume":"8","author":"Martens","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0666","article-title":"MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-830992","article-title":"A CD19\/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15911","article-title":"Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia","volume":"186","author":"Gohil","year":"2019","journal-title":"Br J Haematol"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1472","article-title":"Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells","volume":"101","author":"Kato","year":"1998","journal-title":"J Clin Invest"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.191","article-title":"A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154","volume":"24","author":"Wierda","year":"2010","journal-title":"Leukemia"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1089\/104303401300057360","article-title":"Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes","volume":"12","author":"Takahashi","year":"2001","journal-title":"Hum Gene Ther"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2556","article-title":"Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes","volume":"105","author":"Biagi","year":"2005","journal-title":"Blood"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.03.002","article-title":"An autologous tumor vaccine for CLL","volume":"68","author":"Zhu","year":"2018","journal-title":"Leukemia Res"},{"key":"B246","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B247","doi-asserted-by":"publisher","first-page":"e22892","DOI":"10.4161\/onci.22892","article-title":"Tumor cell recognition by \u03b3\u03b4 T lymphocytes: T-cell receptor vs. NK-cell receptors","volume":"2","author":"Correia","year":"2013","journal-title":"Oncoimmunology"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.02.007","article-title":"NK cell self tolerance, responsiveness and missing self recognition","volume":"26","author":"Shifrin","year":"2014","journal-title":"Semin Immunol"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.2741\/4780","article-title":"Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives","volume":"24","author":"Coscia","year":"2019","journal-title":"Front Biosci (Landmark ed)"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00888","article-title":"The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice","volume":"11","author":"Cerrano","year":"2020","journal-title":"Front Immunol"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00849","article-title":"CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences","volume":"10","author":"Vitale","year":"2020","journal-title":"Front Oncol"},{"key":"B253","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"B254","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.102","article-title":"Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells","volume":"34","author":"Turtle","year":"2016","journal-title":"J Clin Oncol"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.018","article-title":"Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy","volume":"26","author":"Geyer","year":"2018","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A Phase I\/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In\u00a0Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin\u2019s Lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110462","article-title":"Rapid MRD-Negative Responses in Patients with Relapsed\/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1\/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib","volume":"132","author":"Siddiqi","year":"2018","journal-title":"Blood"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127603","article-title":"(uMRD) Responses in Patients with Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1\/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib","volume":"134","author":"Siddiqi","year":"2019","journal-title":"Blood"},{"key":"B268","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1097\/HS9.0000000000000174","article-title":"Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia","volume":"3","author":"Delgado","year":"2019","journal-title":"HemaSphere"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"B270","doi-asserted-by":"publisher","first-page":"e122627","DOI":"10.1172\/jci.insight.122627","article-title":"Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed\/refractory CLL","volume":"5","author":"Geyer","year":"2019","journal-title":"JCI Insight"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125423","article-title":"Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients","volume":"134","author":"Schubert","year":"2019","journal-title":"Blood"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1002\/hon.124_2629","article-title":"PHASE I CLINICAL TRIAL OF CD19-TARGETED 19-28Z\/4-1BBL \u201cARMORED\u201d CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION","volume":"37","author":"Batlevi","year":"2019","journal-title":"Hematol Oncol"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2510","article-title":"Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma","volume":"37","author":"Shah","year":"2019","journal-title":"J Clin Oncol"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000307","article-title":"Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib","volume":"43","author":"Qin","year":"2020","journal-title":"J Immunother (Hagerstown Md 1997)"},{"key":"B277","doi-asserted-by":"publisher","first-page":"18729","DOI":"10.1038\/s41598-019-55239-y","article-title":"Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells","volume":"9","author":"Herrera","year":"2019","journal-title":"Sci Rep"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an \u2018off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol Immunother CII"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-664250","article-title":"Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD","volume":"127","author":"Jacoby","year":"2016","journal-title":"Blood"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792267","article-title":"Dual PD1\/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia","volume":"131","author":"Wierz","year":"2018","journal-title":"Blood"},{"key":"B285","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.59.59","article-title":"Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial","volume":"128","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B288","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s40425-019-0710-1","article-title":"Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200","volume":"7","author":"Mahadevan","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"key":"B290","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117526","article-title":"Phase I\/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed\/Refractory CLL and Richter\u2019s Transformation","volume":"132","author":"Mato","year":"2018","journal-title":"Blood"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15508","article-title":"Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre","volume":"185","author":"Rogers","year":"2019","journal-title":"Br J Haematol"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2777","article-title":"Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies","volume":"24","author":"Khouri","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B293","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004710","article-title":"A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation","volume":"135","author":"Davids","year":"2020","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.594556\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T15:16:24Z","timestamp":1697123784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.594556\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":293,"alternative-id":["10.3389\/fimmu.2020.594556"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.594556","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"article-number":"594556"}}